瑞思邁 RMD 深 滬
已收盤 02-06 16:00:00 美东时间
271.63
+4.580
+1.72%
華盛通- 最 高272.33
- 今 開267.05
- 成交量 150.25万股
- 最 低 267.03
- 昨 收 267.05
- 總市值 395.71亿
- 52周最高 293.21
- 市盈率 靜 28.57
- 換手率 1.03%
- 52周最低 198.19
- 委 比 -45.45%
- 總股本 1.46亿
- 歷史最高 293.21
- 量 比 0.90
- 振 幅 1.98%
- 歷史最低 5.05
- 每 手 1
- 風險率 19.73%
個股概要
財務分析
公司資料
相關新聞
分紅派息
- 分時圖
- 日k
- 周k
- 月k
相關新聞
更多A Look at Becton, Dickinson's Upcoming Earnings Report
Becton, Dickinson (NYSE:BDX) is gearing up to announce its quarterly earnings o...
02-06 22:00
ResMed CFO Brett Sandercock Reports Disposal of Common Shares
ResMed CFO Brett Sandercock Reports Disposal of Common Shares Brett Sandercock, Chief Financial Officer of ResMed Inc., reported a disposal of common shares of the company. The full filing can be accessed through the link below. Disclaimer: This news brief was created by Public Technologies (PUBT) u
02-04 04:07
美股大行评级 | 苹果、SanDisk、西部数据、卡特彼勒、德克斯户外、霍尼韦尔、西南航空、万事达等获多家大行上调目标价
今日重点评级关注：HC Wainwright & Co.：维持Praxis Precision Medicine"买入"评级，目标价从340美元升至1245美元；HC Wainwright & Co.：维持Perspective Therapeutics"买入"评级，目标价从10美元升至12美元
02-02 14:15
ResMed Files Quarterly Form 10-Q for December 2025
Resmed Inc CHESS Depositary Interests on a ratio of 10 CDIs per ord.sh ( ($AU:R...
02-02 05:47
ResMed Reaffirms 2025 Risk Profile: No Material Changes to Previously Disclosed Threats
Resmed Inc (RMD) has disclosed a new risk, in the Regulation category. Resmed I...
01-31 14:00
ResMed Inc. Publishes Transcript of Q2 2026 Earnings Call
ResMed Inc. Publishes Transcript of Q2 2026 Earnings Call ResMed Inc. has published the transcript of its second quarter fiscal year 2026 earnings conference call. The event, held on January 29, 2026, brought together key members of ResMed’s leadership, including the Chief Executive Officer and Chai
01-31 09:05
BUZZ-U.S. STOCKS ON THE MOVE-Church & Dwight, Tesla, Oppenheimer
BUZZ-U.S. STOCKS ON THE MOVE-Church & Dwight, Tesla, Oppenheimer Eikon search string for individual stock moves: STXBZ The Day Ahead newsletter: https://refini.tv/3LI4BU7 The Morning News Call newsletter: https://refini.tv/3dKUyB8 U.S. stocks fell on Friday after President Donald Trump nominated for
01-31 02:38
Analysts Maintain Bull Case On ResMed Despite Competition Concerns
ResMed beat earnings and revenue estimates as sales rose 11% and margins expanded. Analysts backed long-term growth and raised price targets despite competition concerns.
01-31 02:08
Stifel Maintains Hold on ResMed, Raises Price Target to $265
Stifel analyst Jonathan Block maintains ResMed (NYSE:RMD) with a Hold and raises the price target from $260 to $265.
01-30 22:46
ResMed declares $0.60 dividend
ResMed (RMD) declares $0.60/share quarterly dividend, in line with previous. Forward yield 0.93% Payable March 19; for shareholders of record Feb. 12; ex-div Feb. 12. See RMD Dividend Scorecard, Yield...
01-30 16:34
